UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 175

Sortiert nach

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

Clinical cancer research, 2016-08, Vol.22 (15), p.3755-3763

2016

Volltextzugriff (PDF)

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

Annals of oncology, 2015-01, Vol.26 (1), p.113-119

2015

Volltextzugriff (PDF)

Multi-system trajectories and the incidence of heart failure in the Framingham Offspring Study

PloS one, 2022-05, Vol.17 (5), p.e0268576-e0268576

2022

Volltextzugriff (PDF)

Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility

Journal of clinical oncology, 2007-08, Vol.25 (23), p.3525-3533

2007

Volltextzugriff (PDF)

Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways

Annals of oncology, 2016-08, Vol.27 (8), p.1644-1646

2016

Volltextzugriff (PDF)

Deaf and Hard of Hearing Learners With Disabilities: Foundations, Strategies, and Resources

1, 2022

Volltextzugriff (PDF)

Phyllodes tumors of the breast: natural history, diagnosis, and treatment

Journal of the National Comprehensive Cancer Network, 2007-03, Vol.5 (3), p.324

2007

Volltextzugriff (PDF)

Deaf and Hard of Hearing Multilingual Learners: Foundations, Strategies, and Resources

1, 2022

Volltextzugriff (PDF)

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis

Journal of clinical oncology, 2014-09, Vol.32 (25), p.2750-2757

2014

Volltextzugriff (PDF)

A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma

BJU international, 2005-09, Vol.96 (4), p.536-539

2005

Volltextzugriff (PDF)

PCN51 Comprehensive Investigation of Adverse Event (AE)-Related Costs in Patients With Metastatic Breast Cancer (mBC) Treated With First- and Second-Line Chemotherapies

Value in health, 2012-11, Vol.15 (7), p.A418-A418

2012

Volltextzugriff (PDF)

A nonplatinum combination in metastatic transitional cell carcinoma

American journal of clinical oncology, 2005-04, Vol.28 (2), p.114-118

2005

Volltextzugriff (PDF)

A feasibility study to evaluate breast cancer patients’ knowledge of their diagnosis and treatment

Patient education and counseling, 2012-11, Vol.89 (2), p.321-329

2012

Volltextzugriff (PDF)

Abstract P4-12-27: Efficacy and safety of trastuzumab emtansine (T-DM1) vs lapatinib plus capecitabine (XL) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and central nervous system (CNS) metastases: Results from a retrospective exploratory analysis of EMILIA

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-12-27

2013

Volltextzugriff (PDF)

Patient-Reported Outcomes (PROS) From EMILIA, a Phase 3 Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine and Lapatinib (XL) In HER2-Positive Locally Advanced or MBC

Annals of oncology, 2012-09, Vol.23, p.ix120

2012

Volltextzugriff (PDF)

Abstract P5-18-06: Trastuzumab emtansine in HER2-positive metastatic breast cancer: pooled safety analysis from seven studies

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P5-P5-18-06

2012

Volltextzugriff (PDF)

Abstract P5-18-24: Population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of various covariates

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P5-P5-18-24

2012

Volltextzugriff (PDF)

Results from Emilia, A Phase 3 Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine (X) and Lapatinib (L) in Her2-Positive Locally Advanced or Metastatic Breast Cancer (MBC)

Annals of oncology, 2012-09, Vol.23, p.ixe5-ixe6

2012

Volltextzugriff (PDF)

EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS116-TPS116

2011

Volltextzugriff (PDF)

Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells

Biology of blood and marrow transplantation, 2012-01, Vol.18 (1), p.125-133

2012

Volltextzugriff (PDF)

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

Annals of oncology, 2015-01, Vol.26 (1), p.113

2015

Volltextzugriff (PDF)

Abstract P4-12-09: Results from a phase 2a study of trastuzumab emtansine, paclitaxel, and pertuzumab in patients with HER2-positive metastatic breast cancer

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-12-09

2013

Volltextzugriff (PDF)

Gemcitabine and paclitaxel chemotherapy effective for good risk advanced urothelial malignancies

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.4675-4675

2004

Volltextzugriff (PDF)

Gemcitabine and paclitaxel chemotherapy effective for good risk advanced urothelial malignancies

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.4675-4675

2004

Volltextzugriff (PDF)

Reversibility of Trastuzumab Cardiotoxicity : Is the Concept Alive and Well?

Journal of clinical oncology, 2007-12, Vol.25 (34), p.5532-5534

2007

Volltextzugriff (PDF)

1 – 25 von 175

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(135)
Mit Volltextzugriff
(160)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

Multi-system trajectories and the incidence of heart failure in the Framingham Offspring Study

Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility

Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways

Deaf and Hard of Hearing Learners With Disabilities: Foundations, Strategies, and Resources

Phyllodes tumors of the breast: natural history, diagnosis, and treatment

Deaf and Hard of Hearing Multilingual Learners: Foundations, Strategies, and Resources

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis

A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma

PCN51 Comprehensive Investigation of Adverse Event (AE)-Related Costs in Patients With Metastatic Breast Cancer (mBC) Treated With First- and Second-Line Chemotherapies

A nonplatinum combination in metastatic transitional cell carcinoma

A feasibility study to evaluate breast cancer patients’ knowledge of their diagnosis and treatment

Patient-Reported Outcomes (PROS) From EMILIA, a Phase 3 Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine and Lapatinib (XL) In HER2-Positive Locally Advanced or MBC

Abstract P5-18-06: Trastuzumab emtansine in HER2-positive metastatic breast cancer: pooled safety analysis from seven studies

Abstract P5-18-24: Population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of various covariates

Results from Emilia, A Phase 3 Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine (X) and Lapatinib (L) in Her2-Positive Locally Advanced or Metastatic Breast Cancer (MBC)

EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen

Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

Abstract P4-12-09: Results from a phase 2a study of trastuzumab emtansine, paclitaxel, and pertuzumab in patients with HER2-positive metastatic breast cancer

Gemcitabine and paclitaxel chemotherapy effective for good risk advanced urothelial malignancies

Gemcitabine and paclitaxel chemotherapy effective for good risk advanced urothelial malignancies

Reversibility of Trastuzumab Cardiotoxicity : Is the Concept Alive and Well?

Suchergebnisse filtern